Introduction {#s0005}
============

The transcription factor 7-like 2 gene (*TCF7L2*) is one of the genes associated with type 2 diabetes mellitus (T2DM) ([@bb0015], [@bb0020]). In 2007, rs11196218 single nucleotide polymorphism (SNP) in *TCF7L2* was first found associated with T2DM in Hong Kong Chinese ([@bb0065]). Following the initial report, there have been several association studies in different groups ([@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0070], [@bb0100], [@bb0105], [@bb0115]). However, all of these replication studies were carried out in Asian populations, and most of them focused on Chinese ([@bb0035], [@bb0040], [@bb0045], [@bb0070], [@bb0100], [@bb0105], [@bb0115]), especially southern Chinese ([@bb0035], [@bb0045], [@bb0100], [@bb0105], [@bb0115]), except for one Japanese study ([@bb0050]). Although all participants were Asians, the results were confusing rather than conclusive, and showed strong regional variations. Some studies suggested that this SNP was associated with T2DM ([@bb0065], [@bb0115]) while the others reported contradictory results ([@bb0035], [@bb0045], [@bb0100], [@bb0105]). This apparent difference among Asian populations may be due to regional variation or the relatively small sample sizes studied. Two previous meta-analyses had systematically reviewed the association of rs11196218 SNP and risk of T2DM, but one included only 3 studies ([@bb0040]) and the other focused on only Chinese studies ([@bb0090]); neither comprehensively reviewed the association of this SNP and T2DM in Asians.

In the present study, we evaluated the association of rs11196218 polymorphism and T2DM in the Han population in Henan Province in northern China, using a relatively large sample (1842 Chinese individuals with T2DM and 7777 normal glucose-tolerant controls). Then, we combined our data with those of all published studies for a meta-analysis to clarify the association of rs11196218 polymorphism in *TCF7L2* and risk of T2DM in Asians.

Materials and methods {#s0010}
=====================

Study design {#s0015}
------------

A case--control study design was used to evaluate the association of rs11196218 polymorphism in *TCF7L2* and risk of T2DM. The software Sample Size Calculations (Mark Woodward, The George Institute International Health; Lesley Francis, MIS Consultants) was used to calculate the sample size and power. Because the minor allele frequency of rs11196218 is 0.407 in the Chinese population (HapMap-HCB), for an OR of 1.20 for the risk allele, with ratio of controls to cases 4 and two-sided significant level 5%, a total of 8079 participants (1616 cases and 6463 cases) were needed to guarantee 80% statistical power. We conducted a free diabetic screen for the adult residents of two random sampling communities in Henan province, northern China. Those having fasting plasma glucose (FPG) ≥ 7.0 mmol/L or previous diagnosis of T2DM (who was receiving insulin treatment or an oral hypoglycemic agent or presented with a history of diabetes during the interview) were included as cases, while those having FPG \< 7.0 mmol/L and no identifiable positive family history were recruited as controls. In total, 810 cases and 7777 normal glucose-tolerant controls were recruited from community populations. Additionally, we recruited 1032 cases from the outpatient clinics of 3 hospitals in Henan province in order to obtain enough cases. In hospitals, T2DM was diagnosed according to American Diabetes Association (ADA) criterion ([@bb0005]). Participants with body mass index (BMI) ≤ 18.5 kg/m^2^ and who were pregnant, handicapped, mentally disturbed, obese caused by disease or taking certain drugs, and had cancer were excluded. The study was approved by the ethics committee of Zhengzhou University, and informed consent was obtained from each participant before data collection.

Data collection {#s0020}
---------------

Demographic characteristics were collected by interviewer-administered questionnaire. Body weight, body height, waist circumference (WC), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Blood samples were collected for measuring FPG and lipid profile. Total cholesterol (TC), triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) were measured by use of an automatic biochemical analyzer (Hitachi 7600-020, Tokyo, Japan) with reagents purchased from Ningbo Rui Bio-technology (Ningbo, China). Low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula ([@bb0010]). Central obesity based on WC (WC ≥ 85 cm for men or WC ≥ 80 cm for women) was defined according to the recommended criteria for the Chinese population ([@bb0110]).

DNA isolation and genotyping {#s0025}
----------------------------

Genomic DNA was extracted from whole blood by use of a blood genome DNA extraction kit (Yaneng BIO, Shenzhen, China). PCR--ligase detection reaction (PCR--LDR) was used for genotyping. The PCR primers for the loci were 5′-AGC CAT TTC AAT TTC GTA CAT-3′ (forward) and 5′-AAC ATC AAA CTC CAG AGG GTC-3′ (reverse). PCR involved the LabCycler Gradient (SensoQuest GmbH, Göttingen, Germany) in a system with a total volume of 15 μl, containing 1 μl genomic DNA, 1.5 μl 10 × PCR buffer, 1.5 μl MgCl~2~, 0.25 μl each primer, 0.3 μl deoxyribonucleo-tide triphosphate (dNTP), 0.2 μl Taq DNA polymerase (Qiagen GmbH, Hilden, Germany) and 10 μl H~2~O. The cycling parameters were 94 °C for 2 min; 35 cycles at 94 °C for 15 s, 55 °C for 15 s, 72 °C for 25 s; and a final extension step at 72 °C for 3 min. Probe sequences were 5′-AAC CAA CAT GGC TTG TTT TCA TAA A-3′ (A specific), 5′-TTT AAC CAA CAT GGC TTG TTT TCA TAA G-3′ (G specific), and 5′-P-CAC CCG AGA AGG TTT AAA TAA CAT T-FAM-3′ (for LDR). For each PCR product, the ligation reaction was performed in a final volume of 10 μl, including 2 μl PCR product, 1 μl 10 × Taq DNA ligase buffer, 0.03 μl probe mixture, 0.125 μl Taq DNA ligase (New England Biolabs, Beverly, MA, USA) and 7 μl H~2~O. The LDR parameters were 30 cycles at 94 °C for 30 s and 56 °C for 2 min. The LDR reaction products were analyzed on the ABI 377 DNA sequencer (Applied Biosystems). Genotyping success rates in cases and controls were 97.9% and 98.6%, respectively. To confirm the accuracy of the PCR--LDR genotyping method, 5% samples were randomly selected for direct DNA sequencing. PCR--LDR genotyping showed 100% concordance with direct DNA sequencing of the randomly selected PCR products.

Statistical analysis {#s0030}
--------------------

Categorical data are shown as number (percentage) and analyzed by chi-square test. Continuous data are shown as median (Q1, Q3) because data were non-normally distributed. Mann--Whitney--Wilcoxon and Kruskal--Wallis rank tests were used to assess differences in continuous data between cases and controls and among different genotypes in controls, respectively. Odds ratios (ORs), 95% confidence intervals (95% CIs) and corresponding *P* values for risk of T2DM were calculated by binary logistic regression analyses. Sex, age, anthropometric measurements (BMI, WC, SBP and DBP), and lipid levels (TC, TG, HDL-C and LDL-C) were covariates. All tests were two-sided and *P* \< 0.05 was considered statistically significant. Statistical analysis involved SAS version 9.1 for Windows (SAS Institute Inc., NC, USA).

Meta-analysis {#s0035}
-------------

We searched MEDLINE, EMBASE, Cochrane, and Chinese databases (CNKI, CQVIP and Wan-fang Databases) for all articles published in English and Chinese between January 2007 and August 2013 using the keywords "*TCF7L2*", "rs11196218", "genetic polymorphism" and "T2D/T2DM". The meta-analysis involved use of Review Manager version 5.0 (<http://www.cc-ims.net/RevMan>). Crude ORs with 95% CIs were used to assess the strength of association between rs11196218 polymorphism and T2DM risk. The allele model (G vs. A), the co-dominant model (GG vs. AA; AG vs. AA), the dominant model (GG + AG vs. AA) and the recessive model (GG vs. AG + AA) were used to evaluate the risk. Pearson\'s goodness-of-fit chi-square test with 1 degree of freedom was used to assess departure from the Hardy--Weinberg equilibrium (HWE) for the control group in each study. To assess heterogeneity among the studies, Q-test and *I^2^* statistics were used. The fixed-effects model (the Mantel--Haenszel method) was used to calculate the pooled OR with *I^2^* \< 50%; otherwise, the random-effects model was used. Calculation of population-attributable risk proportion (PARP) was based on the estimated OR and risk genotype frequency of the SNP showing significant association with T2DM. Subgroup analyses were performed by region (southern and northern China and Japan).

Results {#s0040}
=======

Association study of rs11196218 polymorphism and T2DM {#s0045}
-----------------------------------------------------

Levels of BMI, WC, SBP, DBP, TC, TG, LDL-C were higher and level of HDL-C was lower for T2DM patients than controls ([Table 1](#t0005){ref-type="table"}). Cases and controls differed in genotype distribution (*P* = 0.001) but not allelic distribution (*P* = 0.579). The AG genotype and dominant model of rs11196218 were associated with risk of T2DM (OR = 1.44, 95% CI = 1.14--1.80; OR = 1.32, 95% CI = 1.06--1.65, respectively) ([Table 2](#t0010){ref-type="table"}). However, after adjusting for sex, age, anthropometric measurements, and lipid levels, only the AG genotype remained associated with risk of T2DM (OR = 1.37, 95% CI = 1.06--1.78), dominant model showed marginal significant associated with risk of T2DM (OR = 1.28, 95% CI = 0.99--1.67) ([Table 2](#t0010){ref-type="table"}). The results changed with WC included as a covariant. When stratified by central obesity status, obese diabetics and non-obese controls differed in genotype distribution (*P* \< 0.001) but not non-obese diabetics and non-obese controls (*P* = 0.637). The rs11196218 genotypes were not associated with clinical characteristics in controls. The power of this study was 100%.

Results of the meta-analysis {#s0050}
----------------------------

We included 9 eligible published articles ([@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0065], [@bb0070], [@bb0100], [@bb0105], [@bb0115]) and current study, for 8342 cases and 13,445 controls. Six studies were for southern China, 3 for northern China, and only one study was for Japan. The distributions of genotypes in controls for all studies were in Hardy--Weinberg equilibrium ([Table 3](#t0015){ref-type="table"}). Because of absence of genotype data, ten studies were used for the allele model, with 8 studies for the other genetic models. We found the dominant model of rs11196218 significantly associated with risk of T2DM in the overall population (OR = 1.20, 95% CI = 1.05--1.36) ([Fig. 1](#f0005){ref-type="fig"}). The PARP for the dominant model was 15.5%. On subgroup analysis by region, the results suggested a consistent association of the dominant model and T2DM risk in southern Chinese (OR = 1.27, 95% CI = 1.01--1.60) but not northern Chinese and Japanese populations. The AG genotype was associated with T2DM risk in southern Chinese (OR = 1.31, 95% CI = 1.03--1.66) ([Table 4](#t0020){ref-type="table"}).

Discussion {#s0055}
==========

T2DM is a complex disease affected by both genetic and environmental factors ([@bb0025]). Many genetic association studies have suggested that several genes and specific SNPs are associated with risk of T2DM ([@bb0055], [@bb0060], [@bb0075], [@bb0095]). In fact, *TCF7L2* is considered the most influential gene in determining genetic susceptibility for T2DM in humans ([@bb0040], [@bb0060], [@bb0070], [@bb0090]). Mechanistic studies suggested that *TCF7L2* could impair β-cell function and down-regulate the expression of glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIP-R), thus reducing insulin level ([@bb0030], [@bb0080], [@bb0085]). However, because of the low frequency of the at-risk allele of the SNP variants rs7903146, rs12255372 and rs11196205, originally reported in European populations, the association of these variants and T2DM in Asian populations varies among studies ([@bb0020]).

In a 2008 study involving a "gene-based approach" to test all common genetic variants within *TCF7L2* in a Chinese population, rs11196218 was found associated with T2DM in Hong Kong Chinese (G vs. A: OR = 1.43, 95% CI = 1.14--1.79) ([@bb0065]). Since then, some replication studies have been performed in Chinese and Japanese populations ([@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0070], [@bb0100], [@bb0105], [@bb0115]); the minor allele frequency (MAF) of rs11196218 was \> 20% in Asians. Even for the common SNP, discrepancies existed among studies performed in the same ethnic groups ([@bb0035], [@bb0045], [@bb0065], [@bb0100], [@bb0105], [@bb0115]). Therefore, with the existing information, evaluating the impact of this gene on the genetic susceptibility of T2DM is difficult. Studies with larger sample size and sufficient power as well as a well-designed meta-analysis are needed to clarify this issue.

With 1842 T2DM and 7777 normal controls in our study, the power to detect the association of rs11196218 polymorphism and T2DM reached 100%. Our results suggest that the GA genotype and the dominant rs11196218 model are associated with risk of T2DM. Our findings are similar to those of Anhui population ([@bb0115]) but opposite to those of Beijing ([@bb0040]), Chongqing ([@bb0105]) and Japan ([@bb0050]) populations. This inconsistence may due to the intricate substructure of study populations, but confounding cannot be neglected. In the present study, the association of the dominant model of rs11196218 polymorphism and T2DM disappeared after adjustment for sex, age, anthropometric measurements, and lipid levels. The results of different adjustments show that WC was the confounder. For controls, we found no association of anthropometric or metabolic measurements and rs11196218 genotypes.

In our meta-analysis, the dominant model of rs11196218 was associated with risk of T2DM in the overall population. However, when stratified by region, this association was found in only the southern Chinese population, not northern Chinese or Japanese populations. In the southern Chinese population, the AG genotype was associated with increased risk of T2DM. The main reason might due to the complex composition of the Chinese and Japanese populations and the great differences among ethnic groups in genetics and living environment. As well, studies of rs11196218 polymorphism and T2DM have focused on southern Chinese populations. Except for our study, with only 2 studies of northern Chinese ([@bb0040], [@bb0070]) and 1 study of Japanese ([@bb0050]), the number of studies is relatively less. More independent replication studies with a large sample size in these regions are needed to verify the results.

Although our study combined data from all qualified studies and had a large sample size with sufficient power to assess the rs11196218 polymorphism in *TCF7L2* in the Asian population, the possible heterogeneity among subjects recruited from different studies might be a limitation. Moreover, we lacked detailed information on sex, age, anthropometric measurements and metabolic measurements for the meta-analysis, so the effects of these factors could not be adequately addressed.

In conclusion, both our case--control study and meta-analysis suggest an association of rs11196218 polymorphism in *TCF7L2* and risk of T2DM in Chinese population.
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###### 

Demographic characteristics of the study participants.

  Characteristics   Cases (n = 1842)        Controls (n = 7777)     *P* value
  ----------------- ----------------------- ----------------------- -----------
  Male              925 (50.2)              3,214 (41.3)            \< 0.001
  Age (year)        54.00 (45.0, 61.0)      49.00 (40.0, 58.0)      \< 0.001
  BMI (kg/m^2^)     27.38 (24.5, 30.7)      23.83 (21.6, 26.2)      \< 0.001
  WC (cm)           90.50 (83.5, 101.3)     81.35 (74.9, 88.5)      \< 0.001
  SBP (mm Hg)       128.33 (120.0, 140.0)   121.33 (110.7, 134.7)   \< 0.001
  DBP (mm Hg)       81.33 (74.0, 90.0)      77.00 (70.7, 85.0)      \< 0.001
  FPG (mmol/L)      7.62 (6.1, 9.9)         5.19 (4.8, 5.5)         \< 0.001
  TC (mmol/L)       4.87 (4.2, 5.6)         4.28 (3.7, 4.9)         \< 0.001
  TG (mmol/L)       1.73 (1.2, 2.6)         1.32 (1.0, 1.9)         \< 0.001
  HDL-C (mmol/L)    1.10 (1.0, 1.3)         1.14 (1.0, 1.3)         \< 0.001
  LDL-C (mmol/L)    2.81 (2.2, 3.4)         2.42 (2.0, 2.9)         \< 0.001

Data are presented as number (%) or median (Q1, Q3).

BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.

###### 

Association of rs11196218 polymorphism and type 2 diabetes mellitus (T2DM) in different models.

  Genetic models      Cases          Controls         *P* value   OR (95% CI)         *P* value[⁎](#tf0005){ref-type="table-fn"}   OR (95% CI)[⁎](#tf0005){ref-type="table-fn"}
  ------------------- -------------- ---------------- ----------- ------------------- -------------------------------------------- ----------------------------------------------
  Allele model                                                                                                                     
   A                  967 (26.82)    4041 (26.37)     --          1.00                --                                           --
   G                  2639 (73.18)   11,287 (73.63)   0.579       0.98 (0.90, 1.06)   --                                           --
  Co-dominant model                                                                                                                
   AA                 98 (5.44)      540 (7.05)       --          1.00                --                                           1.00
   AG                 771 (42.76)    2961 (38.64)     0.002       1.44 (1.14, 1.80)   0.018                                        1.37 (1.06, 1.78)
   GG                 934 (51.80)    4163 (54.31)     0.067       1.24 (0.99, 1.55)   0.173                                        1.20 (0.93, 1.55)
  Dominant model                                                                                                                   
   AA                 98 (5.44)      540 (7.05)       --          1.00                --                                           1.00
   AG + GG            1705 (94.56)   7124 (92.95)     0.014       1.32 (1.06, 1.65)   0.060                                        1.28 (0.99, 1.67)
  Recessive model                                                                                                                  
   AG + AA            869 (48.20)    3501 (45.69)     --          1.00                --                                           1.00
   GG                 934 (51.80)    4163 (54.31)     0.054       0.90 (0.82, 1.00)   0.118                                        0.91 (0.81, 1.02)

Data are presented as number (%).

OR, odds ratio; 95% CI, 95% confidence interval.

Adjusted by sex, age, BMI, WC, SBP, DBP, TC, TG, HDL-C and LDL-C.

###### 

Characteristics of the studies included in the meta-analysis.

  Authors         Year   Region   Source of controls   Genotyping method   Cases   Controls   *P* value[⁎](#tf0010){ref-type="table-fn"}                                                    
  --------------- ------ -------- -------------------- ------------------- ------- ---------- -------------------------------------------- ------ ----- ------ ------ ----- -------- ------ ------
  Current study   --     NC       Community            PCR--LDR            934     771        98                                           2639   967   4163   2961   540   11,287   4041   0.67
  Ng et al.       2007   SC       Community            MALDI-TOF           --      --         --                                           676    190   --     --     --    599      239    --
  Lin et al.      2010   SC       Community            ABI SNaPshot        --      --         --                                           2174   884   --     --     --    2023     855    --
  Luo et al.      2009   NC       Hospital             ABI SNaPshot        250     184        34                                           684    252   257    182    29    696      240    0.67
  Ma et al.       2009   SC       Hospital             PCR-PFLP            93      123        43                                           309    209   67     106    31    240      168    0.30
  Qiao et al.     2012   NC       Hospital             PCR--LDR            382     261        53                                           1025   367   292    235    30    819      295    0.05
  Zhang et al.    2008   SC       Hospital             Taqman              253     210        31                                           716    272   235    153    34    623      221    0.20
  Zheng et al.    2012   SC       Hospital             MALDI-TOF           128     84         15                                           340    114   80     58     14    218      86     0.46
  Zhu et al.      2010   SC       Hospital             Taqman              14      127        159                                          155    445   10     102    188   122      478    0.39
  Miyake et al.   2008   Japan    Community            Taqman              1316    724        93                                           3356   910   1112   612    100   2836     812    0.19

NC, northern China; SC, southern China.

*P* value for Hardy--Weinberg equilibrium.

###### 

Meta-analysis of the association between rs11196218 polymorphism and T2DM in different models.

  Study populations   G vs. A                                              GG vs. AA   AG vs. AA           (GG + AG) vs. AA   GG vs. (AG + AA)                                                                                                                            
  ------------------- ---------------------------------------------------- ----------- ------------------- ------------------ ---------------------------------------------------- ------ ---------------------------------------------------- ------ ------------------- ------
  Overall             1.03 (0.99, 1.08)                                    0.06        1.15 (1.00, 1.33)   0.42               1.16 (0.94, 1.44)[a](#tf0020){ref-type="table-fn"}   0.04   1.20 (1.05, 1.36)                                    0.08   0.97 (0.90, 1.04)   0.40
  Region                                                                                                                                                                                                                                                                  
   Southern China     1.13 (0.99, 1.29)[a](#tf0020){ref-type="table-fn"}   0.04        1.22 (0.89, 1.67)   0.74               1.31 (1.03, 1.66)                                    0.32   1.27 (1.01, 1.60)                                    0.23   0.98 (0.81, 1.18)   0.35
   Northern China     0.98 (0.91, 1.05)                                    0.87        1.08 (0.90, 1.31)   0.09               0.95 (0.55, 1.64)[a](#tf0020){ref-type="table-fn"}   0.01   0.95 (0.62, 1.48)[a](#tf0020){ref-type="table-fn"}   0.02   0.94 (0.86, 1.02)   0.28
   Japan              1.06 (0.95, 1.18)                                    --          1.27 (0.95, 1.71)   --                 1.27 (0.94, 1.72)                                    --     1.27 (0.95, 1.70)                                    --     1.03 (0.91, 1.17)   --

*P* value for heterogeneity.

Estimates for random-effects model.
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